Skip to main content
. Author manuscript; available in PMC: 2021 Dec 20.
Published in final edited form as: Cell Rep. 2021 Aug 24;36(8):109578. doi: 10.1016/j.celrep.2021.109578

Figure 1. Introduction of a p53 gain-of function mutation in KrasG12D PDECs through conditionally active CRISPR-Cas9.

Figure 1.

(A) Experimental design. Representative gross tumors are shown.

(B) Tumor weight. Each dot represents one mouse. n = 6. Error bars, ± SD.

(C) Representative images of tumor sections stained by H&E; scale bars, 100 μm.

(D) mRNA transcript levels as measured by qPCR. The graph shows quantification of the ratio of transcripts for doxorubicin-treated versus untreated cells. Error bars, ± SEM.

(E) Left: representative images of tumor sections stained for CK19, Ki-67, and DAPI by immunofluorescence. Scale bars, 100 μm. Right: Ki-67 quantification per field of view. Each point on the graph represents one mouse; n = 5 (KrasG12D/+; Trp53R172H/+), n = 4 (KrasG12D/+;Trp53+/+). Error bars, ± SD.

For (B), (D), and (E), Student’s t test (two-tailed, unpaired); *p < 0.05, **p < 0.01, ****p < 0.0001.